vs

Side-by-side financial comparison of ENERGIZER HOLDINGS, INC. (ENR) and EXACT SCIENCES CORP (EXAS). Click either name above to swap in a different company.

EXACT SCIENCES CORP is the larger business by last-quarter revenue ($878.4M vs $778.9M, roughly 1.1× ENERGIZER HOLDINGS, INC.). ENERGIZER HOLDINGS, INC. runs the higher net margin — -0.4% vs -9.8%, a 9.3% gap on every dollar of revenue. On growth, EXACT SCIENCES CORP posted the faster year-over-year revenue change (23.1% vs 6.5%). ENERGIZER HOLDINGS, INC. produced more free cash flow last quarter ($124.2M vs $120.4M). Over the past eight quarters, EXACT SCIENCES CORP's revenue compounded faster (17.4% CAGR vs 8.4%).

Energizer Holdings, Inc. is an American manufacturer and one of the world's largest manufacturers of batteries, headquartered in Clayton, Missouri. It produces batteries under the Energizer, Ray-O-Vac, Varta, and Eveready brand names and formerly owned several personal care businesses until it separated that side of the business into a new company called Edgewell Personal Care in 2015.

Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.

ENR vs EXAS — Head-to-Head

Bigger by revenue
EXAS
EXAS
1.1× larger
EXAS
$878.4M
$778.9M
ENR
Growing faster (revenue YoY)
EXAS
EXAS
+16.7% gap
EXAS
23.1%
6.5%
ENR
Higher net margin
ENR
ENR
9.3% more per $
ENR
-0.4%
-9.8%
EXAS
More free cash flow
ENR
ENR
$3.8M more FCF
ENR
$124.2M
$120.4M
EXAS
Faster 2-yr revenue CAGR
EXAS
EXAS
Annualised
EXAS
17.4%
8.4%
ENR

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ENR
ENR
EXAS
EXAS
Revenue
$778.9M
$878.4M
Net Profit
$-3.4M
$-86.0M
Gross Margin
32.9%
70.1%
Operating Margin
-0.6%
-9.4%
Net Margin
-0.4%
-9.8%
Revenue YoY
6.5%
23.1%
Net Profit YoY
-115.2%
90.1%
EPS (diluted)
$-0.45

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ENR
ENR
EXAS
EXAS
Q4 25
$778.9M
$878.4M
Q3 25
$832.8M
$850.7M
Q2 25
$725.3M
$811.1M
Q1 25
$662.9M
$706.8M
Q4 24
$731.7M
$713.4M
Q3 24
$805.7M
$708.7M
Q2 24
$701.4M
$699.3M
Q1 24
$663.3M
$637.5M
Net Profit
ENR
ENR
EXAS
EXAS
Q4 25
$-3.4M
$-86.0M
Q3 25
$34.9M
$-19.6M
Q2 25
$153.5M
$-1.2M
Q1 25
$28.3M
$-101.2M
Q4 24
$22.3M
$-864.6M
Q3 24
$47.6M
$-38.2M
Q2 24
$-43.8M
$-15.8M
Q1 24
$32.4M
$-110.2M
Gross Margin
ENR
ENR
EXAS
EXAS
Q4 25
32.9%
70.1%
Q3 25
36.6%
68.6%
Q2 25
55.1%
69.3%
Q1 25
39.1%
70.8%
Q4 24
36.8%
69.0%
Q3 24
38.1%
69.4%
Q2 24
39.5%
69.8%
Q1 24
38.2%
70.0%
Operating Margin
ENR
ENR
EXAS
EXAS
Q4 25
-0.6%
-9.4%
Q3 25
6.4%
-3.0%
Q2 25
22.6%
-0.3%
Q1 25
5.5%
-13.6%
Q4 24
4.1%
-122.8%
Q3 24
7.4%
-5.6%
Q2 24
-8.2%
-3.8%
Q1 24
6.4%
-16.7%
Net Margin
ENR
ENR
EXAS
EXAS
Q4 25
-0.4%
-9.8%
Q3 25
4.2%
-2.3%
Q2 25
21.2%
-0.1%
Q1 25
4.3%
-14.3%
Q4 24
3.0%
-121.2%
Q3 24
5.9%
-5.4%
Q2 24
-6.2%
-2.3%
Q1 24
4.9%
-17.3%
EPS (diluted)
ENR
ENR
EXAS
EXAS
Q4 25
$-0.45
Q3 25
$-0.10
Q2 25
$-0.01
Q1 25
$-0.54
Q4 24
$-4.69
Q3 24
$-0.21
Q2 24
$-0.09
Q1 24
$-0.60

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ENR
ENR
EXAS
EXAS
Cash + ST InvestmentsLiquidity on hand
$214.8M
$964.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$141.3M
$2.4B
Total Assets
$4.4B
$5.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ENR
ENR
EXAS
EXAS
Q4 25
$214.8M
$964.7M
Q3 25
$236.2M
$1.0B
Q2 25
$171.1M
$858.4M
Q1 25
$139.3M
$786.2M
Q4 24
$195.9M
$1.0B
Q3 24
$216.9M
$1.0B
Q2 24
$146.7M
$946.8M
Q1 24
$158.1M
$652.1M
Total Debt
ENR
ENR
EXAS
EXAS
Q4 25
Q3 25
$3.4B
Q2 25
$3.2B
Q1 25
$3.2B
Q4 24
$3.1B
Q3 24
$3.2B
Q2 24
$3.2B
Q1 24
$3.2B
Stockholders' Equity
ENR
ENR
EXAS
EXAS
Q4 25
$141.3M
$2.4B
Q3 25
$169.9M
$2.5B
Q2 25
$183.2M
$2.5B
Q1 25
$133.9M
$2.4B
Q4 24
$140.6M
$2.4B
Q3 24
$135.8M
$3.2B
Q2 24
$123.4M
$3.2B
Q1 24
$191.3M
$3.1B
Total Assets
ENR
ENR
EXAS
EXAS
Q4 25
$4.4B
$5.9B
Q3 25
$4.6B
$5.9B
Q2 25
$4.5B
$5.8B
Q1 25
$4.2B
$5.7B
Q4 24
$4.2B
$5.9B
Q3 24
$4.3B
$6.7B
Q2 24
$4.2B
$6.7B
Q1 24
$4.3B
$6.4B
Debt / Equity
ENR
ENR
EXAS
EXAS
Q4 25
Q3 25
20.28×
Q2 25
17.57×
Q1 25
23.56×
Q4 24
22.17×
Q3 24
23.51×
Q2 24
26.04×
Q1 24
16.86×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ENR
ENR
EXAS
EXAS
Operating Cash FlowLast quarter
$149.5M
$151.7M
Free Cash FlowOCF − Capex
$124.2M
$120.4M
FCF MarginFCF / Revenue
15.9%
13.7%
Capex IntensityCapex / Revenue
3.2%
3.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$145.0M
$356.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ENR
ENR
EXAS
EXAS
Q4 25
$149.5M
$151.7M
Q3 25
$61.5M
$219.9M
Q2 25
$21.4M
$89.0M
Q1 25
$-12.8M
$30.8M
Q4 24
$77.0M
$47.1M
Q3 24
$168.9M
$138.7M
Q2 24
$45.8M
$107.1M
Q1 24
$36.8M
$-82.3M
Free Cash Flow
ENR
ENR
EXAS
EXAS
Q4 25
$124.2M
$120.4M
Q3 25
$46.7M
$190.0M
Q2 25
$7.9M
$46.7M
Q1 25
$-33.8M
$-365.0K
Q4 24
$42.4M
$10.7M
Q3 24
$141.5M
$112.6M
Q2 24
$27.3M
$71.2M
Q1 24
$10.3M
$-120.0M
FCF Margin
ENR
ENR
EXAS
EXAS
Q4 25
15.9%
13.7%
Q3 25
5.6%
22.3%
Q2 25
1.1%
5.8%
Q1 25
-5.1%
-0.1%
Q4 24
5.8%
1.5%
Q3 24
17.6%
15.9%
Q2 24
3.9%
10.2%
Q1 24
1.6%
-18.8%
Capex Intensity
ENR
ENR
EXAS
EXAS
Q4 25
3.2%
3.6%
Q3 25
1.8%
3.5%
Q2 25
1.9%
5.2%
Q1 25
3.2%
4.4%
Q4 24
4.7%
5.1%
Q3 24
3.4%
3.7%
Q2 24
2.6%
5.1%
Q1 24
4.0%
5.9%
Cash Conversion
ENR
ENR
EXAS
EXAS
Q4 25
Q3 25
1.76×
Q2 25
0.14×
Q1 25
-0.45×
Q4 24
3.45×
Q3 24
3.55×
Q2 24
Q1 24
1.14×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ENR
ENR

Alkaline Batteries$666.5M86%
Auto Care$93.7M12%
Lights$18.7M2%

EXAS
EXAS

Screening$695.1M79%
Precision Oncology$183.2M21%

Related Comparisons